Several viral vector-based gene therapy drugs have now received marketing approval. A
much larger number of additional viral vectors are in various stages of clinical trials for the …

Lentiviral vectors (LVs) are potent tools for the delivery of genes of interest into mammalian
cells and are now commonly utilised within the growing field of cell and gene therapy for the …

The establishment of CRISPR/Cas9 (clustered regularly interspaced short palindromic
repeats/CRISPR-associated protein 9) technology for eukaryotic gene editing opened up …

Viral vectors are potent gene delivery platforms used for the treatment of genetic and
acquired diseases. However, just as viruses have evolved to infect cells efficiently, the …

The concept of gene therapy originated in the mid twentieth century and was perceived as a
revolutionary technology with the promise to cure almost any disease of which the molecular …

Lentiviral vectors (LVs) have emerged as potent and versatile vectors for ex vivo or in vivo
gene transfer into dividing and nondividing cells. Robust phenotypic correction of diseases …

Recombinant adeno-associated viruses (AAVs) have been used widely for in vivo gene
therapy. However, adaptive immune responses to AAV have posed a significant hurdle in …

Although adeno-associated viral (AAV) vectors have been successfully used in hepatic gene
transfer for treatment of hemophilia and other diseases in animals, adaptive immune …

This study reports on the design of mRNA and adjuvant-loaded lipid nanoparticles for
therapeutic cancer vaccination. The use of nucleoside-modified mRNA has previously been …

Self-inactivating (SIN) lentiviral vectors (LV) have an excellent therapeutic potential as
demonstrated in preclinical studies and clinical trials. However, weaker mechanisms of …